PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8099730

2-Chlorodeoxyadenosine in haematological malignancies.

S Castaigne
View original source ↗Export metadata ↓

Abstract

Hereditary adenosine deaminase deficiency results in failure of the lymphocyte development. This occurs because of the accumulation of deoxyadenosine nucleotides. 2-chlorodeoxyadenosine (2CdA) resists the action of adenosine deaminase and accumulates in cells. In doses of 0.1 mg/kg/day given for seven days, 2CdA manifests low toxicity and has been found to be effective in patients with hairy cell leukemia, chronic lymphocytic leukemia, low grade lymphoma and acute myeloid leukemia. 2CdA appears like a very promising drug in these indications.

Explore related subjects

CladribineHumansLeukemiaLymphomaJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Castaigne. 1993. 2-Chlorodeoxyadenosine in haematological malignancies.. https://pubmed.ncbi.nlm.nih.gov/8099730/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Cladribine: an investigational immunomodulatory agent for multiple sclerosis.

OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of cladribine, a purine analog undergoing Phase III trials for approval of its use in the treatment of multiple sclerosis (MS). DATA SOURCES: A MEDLINE search (1966-September 2006) was conducted using the key words cladribine and multiple sclerosis. No limits were placed on the search. STUDY SELECTION AND DATA EXTRACTION: Studies and review articles related to cladribine and MS were reviewed. The trials examining the role of cladribine in MS were analyzed. DATA SYNTHESIS: Cladribine is a purine analog that demonstrates lymphocytotoxic activity. Recent data suggest that cladribine may have a role in the treatment of relapsing-remitting and the progressive forms of MS. In these studies, cladribine has shown mixed results in decreasing neurologic disability, as measured by various rating scales, but has consistently shown positive results in reducing the number of enhancing lesions, which reflects a measure of disease activity. To date, there is one ongoing study examining the role of oral cladribine in the treatment of relapsing-remitting MS. The incidence of adverse effects with cladribine has been significantly greater than with placebo, with the most common being myelosuppression. CONCLUSIONS: While data do not support its use as a first-line MS treatment, cladribine may be a promising agent for refractory patients with secondary progressive MS. Further studies are warranted.

Cladribine↗
PubMed2006

2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.

Hairy cell leukemia is a rare, indolent, chronic lymphoproliferative disorder characterized by the proliferation of a malignant B-cell clone with irregular cytoplasmic projections. Treatment with purine analogs such as 2-chlorodeoxyadenosine (2-CdA) is associated with excellent remission rates and long-term survival. Although the majority of patients achieve a complete remission (CR), most have minimal residual disease detected by sensitive methods. Despite the long term disease-free survival, approximately 36% of patients relapse and many require further therapy. Repeat administration of 2-CdA is very effective in achieving a second CR. Recently, new agents such rituximab and BL22 were shown to be effective in the treatment of relapsed and refractory disease.

Cladribine↗